Lithium carbonate

Generic Name: Lithium carbonate

Brand Names: Carbolith, Lithane, Lithmax, Lithobid

Drug Type: Small Molecule

Chemical Formula: CLi_₂O_₃

CAS Number: 554-13-2

Unique Ingredient Identifier: 2BMD2GNA4V

Background: Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects.

Indication: Lithium carbonate is indicated as a monotherapy for the treatment of acute manic and mixed episodes associated with bipolar 1 disorder in patients ≥7 years of age. It is also indicated as a maintenance treatment for bipolar 1 disorder in patients ≥7 years of age.

Associated Conditions: Bipolar 1 Disorder, Mixed manic depressive episode, Acute Manic episode

Associated Therapies: -

Clinical Trials

Lithium As a Treatment to Prevent Impairment of Cognition in Elders

Phase 4

Completed

Conditions: Mild Cognitive Impairment

Interventions: Drug: Placebo oral capsule
Drug: Lithium Carbonate

First Posted Date: 2017-06-14

Last Posted Date: 2024-08-19

Lead Sponsor: Ariel Gildengers, MD

Target Recruit Count: 80

Registration Number: NCT03185208

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Guidance Model of Standardized Treatment of Antidepressants in Bipolar Disorder

Phase 4

Conditions: the Use of Antidepressants in Patients With Bipolar Depression

Interventions: Drug: lithium carbonate combined with SSRI antidepressant treatment
Drug: Lithium Carbonate

First Posted Date: 2017-05-11

Last Posted Date: 2017-05-11

Lead Sponsor: Peking University

Target Recruit Count: 100

Registration Number: NCT03148535

Locations: 🇨🇳
The first hospital of Hebei Province University, Shijiazhuang, Hebei, China
🇨🇳
Dalian No.7 People's Hospital, Dalian, Liaoning, China
🇨🇳
Institute of mental health, Peking University, Beijing, Beijing, China

and more 1 locations

Lithium in Acute Kidney Injury

Phase 4

Conditions: Acute Kidney Injury

Interventions: Drug: Placebo oral capsule
Drug: Lithium Carbonate

First Posted Date: 2017-02-17

Last Posted Date: 2017-02-17

Lead Sponsor: Lifespan

Target Recruit Count: 50

Registration Number: NCT03056248

Lithium for Fracture Treatment: a Double Blind Randomized Controlled Trial (LiFT)

Phase 2

Recruiting

Conditions: Fractures

Interventions: Drug: Lithium Carbonate
Drug: Lactose Placebo

First Posted Date: 2016-12-21

Last Posted Date: 2024-01-26

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 160

Registration Number: NCT02999022

Locations: 🇨🇦
The Ottawa Hospital Civic Campus, Ottawa, Ontario, Canada
🇨🇦
Royal Victoria Regional Health Centre, Barrie, Ontario, Canada
🇨🇦
Hamilton Health Sciences, Hamilton, Ontario, Canada

and more 2 locations

Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode

Phase 4

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Lithium Carbonate
Drug: Sertraline
Drug: Nortriptyline
Drug: Risperidone

First Posted Date: 2016-09-28

Last Posted Date: 2020-11-20

Lead Sponsor: Federal University of Rio Grande do Sul

Target Recruit Count: 78

Registration Number: NCT02918097

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated

Conditions: Bipolar Disorder

First Posted Date: 2016-09-08

Last Posted Date: 2024-03-12

Lead Sponsor: University of New Mexico

Target Recruit Count: 1037352

Registration Number: NCT02893371

Locations: 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States

Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia

Phase 2

Completed

Conditions: Frontotemporal Dementia (FTD)

Interventions: Drug: Lithium Carbonate
Drug: Placebo

First Posted Date: 2016-08-10

Last Posted Date: 2023-11-22

Lead Sponsor: Columbia University

Target Recruit Count: 17

Registration Number: NCT02862210

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment

Not Applicable

Completed

Conditions: Mild Cognitive Impairment

Interventions: Drug: Lithium Carbonate

First Posted Date: 2015-11-10

Last Posted Date: 2021-08-09

Lead Sponsor: University of Dundee

Target Recruit Count: 11

Registration Number: NCT02601859

Evaluation of Lithium and It's Effect on Clinically Localized Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Lithium Carbonate

First Posted Date: 2014-07-24

Last Posted Date: 2017-01-09

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 11

Registration Number: NCT02198859

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Randomized, Placebo-controlled Multicenter Trial of Lithium Plus Treatment as Usual (TAU) for Acute Suicidal Ideation and Behavior in Patients With Suicidal Major Depressive Episode

Not Applicable

Conditions: Suicidal Ideation/Behavior
Depression

Interventions: Drug: Placebo
Drug: Lithium Carbonate

First Posted Date: 2014-01-17

Last Posted Date: 2018-03-15

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 254

Registration Number: NCT02039479

Locations: 🇩🇪
Psychiatrie, Verhaltensmedizin und Psychosomatik, Chemnitz, Germany
🇩🇪
Psychatrie Universitätsmedizin Göttingen, Göttingen, Germany
🇩🇪
Dept. of Psychiatry and Psychotherapy, Hospital of Dresden Neustadt, Dresden, Saxony, Germany

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy